Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Combined Treatment with Stattic and Docetaxel Alters the Bax/Bcl-2 Gene Expression Ratio in Human Prostate Cancer Cells

1 Nov 2016

Abstract excerpt

Docetaxel, recognized as a stabilizing microtubule agent, is frequently administrated as a first line treatment for prostate cancers. Due to high side effects of monotherapy, however, combinations with novel adjuvants have emerged as an alternative strategy in cancer therapy protocols. Here, we investigated the combined effects of stattic and docetaxel on the DU145 prostate cancer cell line. Cytotoxicity was...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cancer-related Molecular Pathways
Share to Cell death mechanisms and regulation
Share to Cytokine Signaling Pathways and Interactions

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 28032735
DOI: 10.22034/apjcp.2016.17.11.5031

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 3 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Combined Treatment with Stattic and Docetaxel Alters the Bax/Bcl-2 Gene Expression Ratio in Human Prostate Cancer CellsPMID 28032735Read ↗

Efficacy and safety of the combination of docetaxel (Taxotere) with targeted therapies in the treatment of solid malignancies.Semantic proximity Read ↗

Silencing of miR-193a-5p increases the chemosensitivity of prostate cancer cells to docetaxelSemantic proximity Read ↗

Breast cancer cells respond differently to docetaxel depending on their phenotype and on survivin upregulation.Semantic proximity Read ↗

Novel role of Stat1 in the development of docetaxel resistance in prostate tumor cellsSemantic proximity Read ↗

Combination Treatment with Docetaxel and Phytol or Thymol additively Inhibits Proliferation of Breast Cancer Cells and Down Regulate Expression of Cancer Stem Cell MarkersSemantic proximity Read ↗

Protein Disulfide Isomerase 4 Drives Docetaxel Resistance in Prostate CancerSemantic proximity Read ↗

Docetaxel induces cell death through mitotic catastrophe in human breast cancer cellsSemantic proximity Read ↗

Activation of the mitochondria-driven pathway of apoptosis in human PC-3 prostate cancer cells by a novel hydrophilic paclitaxel derivative, 7-xylosyl-10-deacetylpaclitaxelSemantic proximity Read ↗

CIL-102 Interacts with Microtubule Polymerization and Causes Mitotic Arrest following Apoptosis in the Human Prostate Cancer PC-3 Cell LineSemantic proximity Read ↗

Tubulin-Targeted Agents Including Docetaxel and CabazitaxelSemantic proximity Read ↗

Acquisition of chemoresistant phenotype by overexpression of the antiapoptotic gene testosterone-repressed prostate message-2 in prostate cancer xenograft models.Semantic proximity Read ↗

MiR-204 enhances mitochondrial apoptosis in doxorubicin-treated prostate cancer cells by targeting SIRT1/p53 pathwaySemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.